Sorrento Has Potential To Deliver Multiple Best-In-Class Products

• Cantor Fitzgerald initiated coverage on Sorrento Therapeutics Inc (NASDAQ: SRNE) with an Overweight rating and a price target of $5.

• The analyst says Sorrento has the potential to deliver multiple best-in-class products in high-value areas of oncology, pain, and infectious disease, highlighting three value drivers:

  • Scilex’s potential in non-opioid pain. Its pain portfolio currently has marketed and pipeline programs, which could unlock further meaningful value.

  • Abivertinib’s potential in non-small cell lung cancer

  • A conservative platform value is believed to allow investors to be rewarded from current levels over the near term and over the longer term as other pipeline programs come to the fore.

• In August, abivertinib showed significant treatment benefits in 209 response-evaluable, heavily pretreated NSCLC patients, with an ORR of 56.5%.

• A significant CR rate was seen with Abivertinib (5.3%) compared to AstraZeneca Plc’s (NASDAQ: AZN) Tagrisso (osimertinib) (0.5%), overall survival of 28.2 months (versus Tagrisso’s median OS of 26.8 months).

• Price Action: SRNE shares are down 0.95% at $1.57 on the last check Wednesday.

Latest Ratings for SRNE

Date	Firm	Action	From	To
Aug 2021	HC Wainwright & Co.	Maintains		Buy
Jan 2021	Alliance Global Partners	Initiates Coverage On		Buy
Jul 2020	HC Wainwright & Co.	Maintains		Buy

View More Analyst Ratings for SRNE

View the Latest Analyst Ratings

See more from Benzinga

Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.